Early Detection Blood Tests
Blinded Reference Set for Multicancer Early Detection Blood Tests
What will happen during the trial?
PRIMARY OBJECTIVE:
I. To provide a blinded reference set of cancer versus (vs.) non-cancer blood samples that will be used to validate assays for inclusion in a prospective clinical trial focused on utility of blood-based multi-cancer early detection.
SECONDARY OBJECTIVES:
I. Evaluate test performance at the time of initial cancer diagnosis by tumor type.
II. Evaluate test performance at the time of initial cancer diagnosis by clinical stage.
OUTLINE:
Participants complete a questionnaire at baseline. Participants undergo collection of blood samples at registration and at 12 months after registration. Patients with a cancer diagnosis may undergo collection of tissue samples at registration and 12 months after registration.
After completion of study, participants are followed up at 1 year.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Observational Trial
- Enrollment
- 2,000 patients (estimated)
- Sponsors
- Alliance for Clinical Trials in Oncology
- Collaborators
- National Cancer Institute (NCI)
- Trial Type
- Observational
- Last Update
- 2 weeks ago
- SparkCures ID
- 1808
- NCT Identifier
- NCT05334069
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.